News articles about Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Aurinia Pharmaceuticals earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.7278343900905 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the news headlines that may have impacted Accern’s rankings:

Shares of Aurinia Pharmaceuticals (NASDAQ AUPH) traded down 0.82% on Friday, reaching $6.02. The company’s stock had a trading volume of 189,870 shares. Aurinia Pharmaceuticals has a 1-year low of $1.88 and a 1-year high of $10.54. The company’s market capitalization is $502.58 million. The stock has a 50-day moving average price of $6.29 and a 200-day moving average price of $6.35.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.10. Aurinia Pharmaceuticals had a negative return on equity of 28.61% and a negative net margin of 16,648.93%. The business had revenue of $0.33 million during the quarter, compared to analyst estimates of $0.06 million. On average, equities research analysts forecast that Aurinia Pharmaceuticals will post ($1.00) EPS for the current year.

AUPH has been the topic of several analyst reports. HC Wainwright cut their target price on Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Thursday, May 18th. Zacks Investment Research upgraded Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Vetr lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.74 target price on the stock. in a research note on Monday, July 31st. Cantor Fitzgerald set a $14.00 target price on Aurinia Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 11th. Finally, BidaskClub lowered Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. Aurinia Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $9.72.

TRADEMARK VIOLATION NOTICE: “Aurinia Pharmaceuticals (AUPH) Getting Somewhat Favorable News Coverage, Analysis Shows” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Insider Buying and Selling by Quarter for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Stock Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.